Purevax RCPCh Den Europæiske Union - portugisisk - EMA (European Medicines Agency)

purevax rcpch

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - imunológicos para felidae, - gatos - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. os começos de imunidade foram demonstrados uma semana após o curso de vacinação primária para rinotraqueíte, calicivírus, chlamydophila felis e componentes de panleucopenia. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Purevax RCPCh FeLV Den Europæiske Union - portugisisk - EMA (European Medicines Agency)

purevax rcpch felv

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - imunológicos para felidae, - gatos - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Zulvac 8 Bovis Den Europæiske Union - portugisisk - EMA (European Medicines Agency)

zulvac 8 bovis

zoetis belgium - vírus inactivado da febre catarral ovina, serotipo 8, estirpe btv-8 / bel2006 / 02 - imunologias - gado - active immunisation of cattle from three months of age for the prevention of viraemia caused by bluetongue virus, serotype 8.

Zabdeno Den Europæiske Union - portugisisk - EMA (European Medicines Agency)

zabdeno

janssen-cilag international n.v.    - recombinant adenovirus type 26 (ad26) encoding the glycoprotein (gp) of the ebola virus zaire (zebov) mayinga strain - febre hemorrágica Ébola - vacinas - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

Mvabea Den Europæiske Union - portugisisk - EMA (European Medicines Agency)

mvabea

janssen-cilag international n.v.    - recombinant modified vaccinia ankara bavarian nordic virus encoding the: ebola virus zaire (zebov) mayinga strain glycoprotein (gp); ebola virus sudan gulu strain gp; ebola virus taï forest strain nucleoprotein and the marburg virus musoke strain gp - febre hemorrágica Ébola - vacinas - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

Apexxnar Den Europæiske Union - portugisisk - EMA (European Medicines Agency)

apexxnar

pfizer europe ma eeig - pneumococcal polysaccharide serotype 1, pneumococcal polysaccharide serotype 3, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 5, pneumococcal polysaccharide serotype 6a, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 7f, pneumococcal polysaccharide serotype 8, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 10a, pneumococcal polysaccharide serotype 11a, pneumococcal polysaccharide serotype 12f, pneumococcal polysaccharide serotype 14, pneumococcal polysaccharide serotype 15b, pneumococcal polysaccharide serotype 18c, pneumococcal polysaccharide serotype 19a, pneumococcal polysaccharide serotype 19f, pneumococcal polysaccharide serotype 22f, pneumococcal polysaccharide serotype 23f, pneumococcal polysaccharide serotype 33f - infecções pneumocócicas - vacinas - active immunisation for the prevention of invasive disease and pneumonia caused by streptococcus pneumoniae in individuals 18 years of age and older. veja as seções 4. 4 e 5. 1 para informações sobre proteção contra serotipos pneumocócicos específicos. apexxnar should be used in accordance with official recommendations. .

Zoonotic Influenza Vaccine Seqirus Den Europæiske Union - portugisisk - EMA (European Medicines Agency)

zoonotic influenza vaccine seqirus

seqirus s.r.l.  - zoonotic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted), influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza a virus, h5n1 subtype - vacinas - active immunisation against h5 subtype of influenza a virus.

Audret 3 mg/ml Colírio, solução Portugal - portugisisk - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

audret 3 mg/ml colírio, solução

laboratório edol - produtos farmacêuticos, s.a. - ofloxacina - colírio, solução - 3 mg/ml - ofloxacina 3 mg/ml - ofloxacin - n/a - duração do tratamento: curta ou média duração

Audret 3 mg/ml Colírio, solução Portugal - portugisisk - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

audret 3 mg/ml colírio, solução

laboratório edol - produtos farmacêuticos, s.a. - ofloxacina - colírio, solução - 3 mg/ml - ofloxacina 3 mg/ml - ofloxacin - n/a - duração do tratamento: curta ou média duração

Audret 3 mg/ml Colírio, solução Portugal - portugisisk - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

audret 3 mg/ml colírio, solução

laboratório edol - produtos farmacêuticos, s.a. - ofloxacina - colírio, solução - 3 mg/ml - ofloxacina 3 mg/ml - ofloxacin - n/a - duração do tratamento: curta ou média duração